BioNTech Expands COVID-19 Vaccine Output Again, Forecasts $10bn Revenues

Also Increasing Oncology Trials

 
• By Andrew McConaghie
  
Mainz, Rheinland-Pfalz, Germany-9. September 2020 Biontech building in Mainz with the sun shining and waving flags
BioNTech has been transformed into a European biotech powerhouse, with a market cap of $26bn and vaccines revenues to fund its ambitions in immunotherapy.
Scrip Podcast

Keep up with the top pharma business news of the week. On the go.

Scrip brings you a weekly bulletin of top picks.

SpotifyApple PodcastsWebsite

More from Business

More from Scrip